Related Experiment Videos
Future directions in lipid therapies
1UCLA Center for Primary Care-Based Cardiovascular Disease Prevention, Los Angeles, California 90095, USA.
Insights
Effective cholesterol management remains crucial for reducing cardiovascular disease. New therapies and statins offer improved lipid profiles, helping more patients reach treatment goals and lower cardiovascular event risk.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Cardiovascular disease (CVD) is a major public health concern, with lipid abnormalities being significant risk factors.
- Despite available therapies and guidelines, many high-risk patients do not achieve target lipid levels.
- Statins are widely prescribed due to efficacy and tolerability, but further improvements are needed.
Purpose of the Study:
- To review current and emerging strategies for cholesterol management.
- To highlight advancements in lipid-lowering therapies and their potential impact on cardiovascular event reduction.
- To discuss the role of novel agents and combination therapies in achieving treatment goals.
Main Methods:
- Review of current literature on lipid-lowering drug classes (fibrates, niacin, resins, statins).
- Discussion of newer formulations and agents in development, including cholesterol-absorption inhibitors and ACAT inhibitors.
- Analysis of potential benefits of combination therapies for dyslipidemia.
Main Results:
- Statins are the most prescribed agents due to high efficacy and tolerability.
- Newer statin formulations and novel niacin/resin forms may offer improved efficacy and fewer side effects.
- Emerging agents like cholesterol-absorption inhibitors and ACAT inhibitors, especially in combination with statins, show promise for greater lipid profile improvements.
Conclusions:
- Innovations in cholesterol-lowering therapies are essential for improving patient outcomes.
- Achieving more aggressive cholesterol goals is possible with advanced treatments.
- These advancements are expected to significantly reduce the risk of cardiovascular events.
Abstract:
Cholesterol management to reduce the burden of cardiovascular disease is a major public health concern. Despite widespread recognition of lipid abnormalities as cardiovascular risk factors, significant cardiovascular event reductions with cholesterol-lowering therapies, and dissemination of treatment guidelines, most high-risk patients are not at target lipid levels. In addition to lifestyle changes, four major drug classes are available to modify lipid levels: fibrates, niacin, resins, and statins. High efficacy and tolerability in clinical trials make statins the most widely prescribed of these agents. Newer, more potent members of this class and novel formulations of niacin and resins may provide more effective therapy for dyslipidemia with fewer side effects. Several agents in development (cholesterol-absorption inhibitors and ACAT inhibitors) exploit mechanisms of action complementary to those of current treatments and combined with statins may produce greater improvements in lipid profiles than are now possible. These innovations should enable a greater number of patients to achieve more aggressive cholesterol goals, thereby reducing the risk of cardiovascular events.